면역관문억제제 병용 전략 본격화 신라젠 CI.관련 키워드신라젠티슬렐리주맙FDA오가노이드비원메디슨문대현 기자 Kangstem Biotech CSO Professor Kang Kyung-sun Confirms Therapeutic Potential of Vascularized Artific...Beyond Approval to Insurance Coverage: Medical AI Companies Turn to Real-World Evidence to Drive Ado...